Qu Zhang

Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study.

M. Rebelatto, J. W. Kim, P. Mccoon, 2022, The lancet. Gastroenterology & hepatology.

Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide

D. Petrylak, M. Fleming, R. Cathomas, 2021, Clinical Cancer Research.

Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade.

Song Wu, J. Barrett, M. Hellmann, 2020, Cancer discovery.

Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure.

R. Ferris, L. Licitra, R. Haddad, 2020 .

Excellent response of refractory triple-negative breast cancer to sintilimab plus chemotherapy: a case report.

D. Hu, G. Han, Qu Zhang, 2023, Immunotherapy.

Molecular biomarkers to identify patients (pts) who may benefit from durvalumab (D; anti-PD-L1) ± tremelimumab (T; anti-CTLA-4) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) from HAWK and CONDOR studies.

A. Matakidou, L. Siu, Z. Ghazoui, 2020 .

Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC).

M. Rebelatto, J. W. Kim, D. Oh, 2020 .

Abstract 5717: LncRNA RP11-291B21.2 is associated with Durvalumab response in NSCLC and BLCA cancers

Song Wu, A. Gupta, Sarah C. Hsu, 2020 .

Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

L. Siu, L. Licitra, R. Haddad, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.